首页
登录
职称英语
Under existing law, a new drug may be labeled, promoted, and advertised only
Under existing law, a new drug may be labeled, promoted, and advertised only
游客
2023-12-18
18
管理
问题
Under existing law, a new drug may be labeled, promoted, and advertised only for those conditions in which safety and effectiveness have been demonstrated and of which the Food and Drug Administration (FDA) has approved, or so-called "approved uses." Other uses have come to be called "unapproved uses" and cannot be legally promoted. In a real sense, the term "unapproved’ is a misnomer because it includes in one phrase two categories of marketed drugs that are very different; drugs which are potentially harmful and will never be approved, and already approved drugs that have "unapproved" uses. It is common for new research and new insights to demonstrate valid new uses for drugs already on the market. Also, there are numerous examples of medical progress resulting from the serendipitous observations and therapeutic innovations of physicians, both important methods of discovery in the field of therapeutics. Before such advances can result in new indications for inclusion in drug labeling, however, the available data must meet the legal standard of substantial evidence derived from adequate and well-controlled clinical trials. Such evidence may require time to develop, and, without initiative on the part of the drug firm, it may not occur at all for certain uses. However, because medical literature on new uses exists and these uses are medically beneficial, physicians often use these drugs for such purposes prior to FDA review or changes in labeling. This is referred to as "unlabeled uses" of drugs.
A different problem arises when a particular use for a drug has been examined scientifically and has been found to be ineffective or unsafe, and yet physicians who either are uninformed or who refuse to accept the available scientific evidence continue to use the drug in this way. Such use may have been reviewed by the FDA and rejected, or, in some cases, the use may actually be warned against in the labeling. This subset of uses may be properly termed "disapproved uses."
Government policy should minimize the extent of unlabeled uses. If such uses are valid--and many are- it is important that scientifically sound evidence supporting them be generated and that the regulatory system accommodate them into drug labeling. Continuing rapid advances in medical care and the complexity of drug usage, however, makes it impossible for the government to keep drug labeling up to date for every conceivable situation. Thus, when a particular use of this type appears, it is also important, and in the interest of good medical care, that no stigma be attached to "unapproved usage" by practitioners while the formal evidence is assembled between the time of discovery and the time the new use is included in the labeling. In the case of "disapproved uses," however, it is proper policy to warn against these in the package insert, whether use of a drug for these ’purposes by the uninformed or intransigent physician constitutes a violation of the current Federal Food, Drug and Cosmetic Act is a matter of debate that involves a number of technical and legal issues. Regardless of that, the inclusion of disapproved uses in the form of contraindications, warnings and other precautionary statements in package inserts is an important practical deterrent to improper use. Except for clearly disapproved uses, however, it is in the best interests of patient care that physicians not be constrained by regulatory statutes from exercising their best judgment in prescribing a drug for both its approved uses and any unlabeled uses it may have. [br] It can be inferred from the passage that the intransigent physician______.
选项
A、continues to prescribe a drug even though he knows it is not in the best interests of the patient
B、refuses to use a drug for an unlabeled purpose out of fear that he may be stigmatized by its use
C、persists in using a drug for disapproved uses because he rejects the evidence of its ineffectiveness or dangers
D、experiments with new uses for tested drugs in an attempt to find medically beneficial uses for the drugs
答案
C
解析
这是一道推断题。应从文章的两个基本点来分析所获得的信息,在第二段中作者认为有些医生坚持将被禁止过的药品用于医疗用途出于两种原因:要么是忽略、要么是拒绝接受事实,然后在第三段中所指的那些医生违背药品使用规定,不是uninformed,就是intransigent。两段中的平行内容告诉我们 intransigent physician指的是那些拒绝接受药品尤疗效事实的医生。这种含义与C的内容完全相符。A是错的,因为intransigent physician所开的药是违反规定的,但医生本人坚持认为是有效的。B也是错的,因为这种医生不会去冒险。至于D,一个intransigent physician可能会采取一些行动,但该内容不符合问题中所说的intransigent physician的定义,故是错的。
转载请注明原文地址:https://tihaiku.com/zcyy/3284755.html
相关试题推荐
【B1】[br]【B5】existed→existing此处technologies前为分词作定语,exist为不及物动词,不能用过去分词表示被动。因为是指
Nowadayswiththedevelopmentofeconomy,existingcitiesaregrowingbigger
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonly
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonly
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonly
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonly
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonlyf
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonlyf
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonlyf
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonlyf
随机试题
Forallthetalkofhissustainedadolescence,noperformermadeamorecomp
Giventhechoicebetweenspendinganeveningwithfriendsandtakingextrat
AfterthreeyearsatNewYorkUniversity,Ileftatthetimetotakeasix-m
侧支抑制是()A.运动神经元轴突发出的侧支所引起 B.经过兴奋性中间神经元起
根据下面材料,回答题 南部苏丹于当地时间2011年7月9日宣布正式从苏丹分离
( )即基金份额的持有人、基金产品的投资人,是基金资产的所有者和基金投资回报的
A.140~159/90~99mmHg B.140~149/90~94mmHg
各种运输方式内外部的各个方面的构成和联系,就是( )。 A.运输系统
教师的职业形象主要包括( )A、 教师的道德形象 B、 教师的文化形象 C、
A. B. C. D. E.单室模型静脉滴注和静脉注射联合用药,首剂量(
最新回复
(
0
)